425: Strive & Semler Merge for Bitcoin Treasury Scale

Strive and Semler Scientific announce a strategic merger to scale Bitcoin holdings and expand digital credit offerings, targeting significant long-term growth.

Summary

• Strive, Inc. and Semler Scientific, Inc. are pursuing a proposed business combination, with Semler shareholders currently voting until January 13, 2026, with both companies recommending a 'yes' vote.
• The merger aims to significantly scale the combined entity's Bitcoin holdings, leveraging Semler's existing 5,000+ Bitcoin and Strive's digital credit strategy.
• Strive emphasizes its 'Bitcoin as the hurdle rate' philosophy and its unique position with 30% amplification through perpetual preferred equity, a level MicroStrategy aims to achieve by 2029-2030.
• Strive's digital credit product, SATA, saw its IPO upsized from $125 million to $200 million and was over two times oversubscribed, with an interest rate recently increased to 12.25% (effective yield over 13%).
• The companies plan to retire Semler's convertible note, potentially through selling Bitcoin or issuing new SATA stock to maintain the 30% amplification ratio.
• Beyond Bitcoin, the merger seeks to unlock value in Semler's preventative healthcare business, with a new product for early heart disease prevention awaiting FDA approval in 2026.
• Management expresses strong conviction in Bitcoin's long-term fundamentals, citing ETF demand exceeding daily mining supply and a potential price in the millions when compared to gold's market cap.

Sentiment

Score: 9

Explanation: The filing conveys a highly optimistic and confident sentiment regarding the merger's strategic benefits, the future of Bitcoin, and the potential of digital credit. Management's language is consistently bullish, emphasizing significant upside and innovation, with risks acknowledged but not overshadowing the positive outlook.

Positives

• The merger creates a larger combined Bitcoin treasury, enhancing scale and market presence.
• Strive's innovative digital credit strategy, amplified by 30% through perpetual preferred equity, offers a unique investment structure in the Bitcoin space.
• Strong demand for Strive's SATA digital credit, evidenced by an oversubscribed IPO and an attractive 12.25% interest rate (over 13% effective yield), indicates market confidence.
• Potential for significant value creation in Semler's medical business, particularly with a new heart disease prevention product awaiting FDA approval in 2026.
• Management holds a highly bullish long-term outlook for Bitcoin, driven by strong fundamentals, ETF demand, and comparison to gold's market capitalization.
• The merger provides Semler shareholders an opportunity to benefit from Strive's growth and the combined company's larger Bitcoin holdings.

Negatives

• Semler Scientific's core medical business previously encountered regulatory headwinds, which prompted its pivot to Bitcoin treasury strategy.

Risks

• The merger agreement could be terminated by either Strive or Semler Scientific.
• The proposed transaction may not close as expected or at all if closing conditions are not met timely.
• Legal proceedings could be instituted against Strive, Semler Scientific, or the combined company.
• Anticipated benefits, including cost savings and strategic gains, may not be realized due to changes in Bitcoin treasury strategies, general economic conditions, interest/exchange rates, monetary policy, or regulatory enforcement.
• Integration of the two companies could be more difficult, time-consuming, or costly than anticipated.
• The transaction may incur higher expenses or take longer to complete due to unexpected factors.
• Management's attention may be diverted from ongoing business operations and opportunities during the merger process.
• Strive's issuance of additional Class A common stock in connection with the merger could cause dilution for existing shareholders.
• There is a risk of adverse reactions from customers or changes to business or employee relationships following the announcement or completion of the transaction.
• Changes in Strive's or Semler Scientific's share price before closing could impact the transaction.

Future Outlook

The combined company anticipates significant growth by scaling its Bitcoin holdings and expanding its digital credit offerings, which are positioned to outperform traditional fixed income and fiat currency debasement. Semler Scientific expects FDA approval for a new heart disease prevention product in 2026, potentially unlocking substantial value in its medical business. Management maintains a strong long-term bullish outlook on Bitcoin, projecting a price in the millions based on its comparison to gold's market capitalization and increasing institutional demand through ETFs.

Management Comments

• "The vote is actually now live, so the vote will will wrap up for Semler shareholders... both sides are recommending a yes vote."
• "We Semler Scientific, we were the second company in the US, second public company to adopt Bitcoin as treasury... we ended up buying over 5000 Bitcoin."
• "Our core business... ran into some regulatory headwinds, and we were approached by Strive... to see if we had an interest in merging."
• "For us, it was really critical to get to scale in our Bitcoin holdings... teaming up with Matt and Vivek... would be the best way for Semler shareholders to kind of get to the next plateau."
• "We saw real synergies on our medical business, and are hopeful that the Strive team can create value on that side as well."
• "The question becomes, what is the most effective way to set and implement Bitcoin as the hurdle rate as an operating business... I think digital credit is the best opportunity."
• "Scale is something that bringing Strive and Semler together does in a major way... we are already 30% amplified through preferreds."
• "We've publicly stated intentions to retire [Semler's convertible note]... likely a better way if market conditions allowed it would be to issue new SATA stock."
• "There is a lot of demand for digital credit... we've also recently upsized the interest rate on SATA to 12.25%."
• "Fixed income is dead... digital credit... allows for income that actually grows faster than the rate of fiat currency debasement, not slower."
• "The biggest one that's underappreciated is is the potential for value to be unlocked on someone's operating business... if we're able to leverage some of the people around Strive... is unlocking value there."
• "We do have a product that we're waiting for FDA approval for, for early prevention of heart disease... that should hopefully come out of the FDA next year."
• "The tailwinds here for for Bitcoin are just unbelievably positive for the next three to five years... everything, from a fundamental perspective for Bitcoin, has literally never been stronger."
• "Bitcoin ETFs are literally just beginning... the demand into those ETFs is greater than the Bitcoin being mined each day."
• "Bitcoin should trade closer to the value of gold, and that spread is obviously widened recently. So there's just, I think, more upside to that thesis."
• "Do the math on the ratio of market caps between Bitcoin versus gold today... and you're going to find something in the millions of dollars."

Industry Context

This merger highlights a growing trend among public companies to adopt Bitcoin as a treasury asset, seeking to leverage its potential for appreciation and hedge against fiat currency debasement. Strive's focus on 'digital credit' through perpetual preferred equity positions it as an innovator in financing Bitcoin-backed strategies, differentiating itself from traditional debt structures and offering a new income-generating instrument. The discussion also reflects the increasing institutional adoption of Bitcoin, particularly through ETFs, which is driving demand beyond daily mining supply.

Comparison to Industry Standards

• Semler Scientific was the second U.S. public company to adopt Bitcoin as a treasury asset, following MicroStrategy (Strategy).
• Strive was the second issuer of digital credit in the market, also following MicroStrategy (Strategy).
• Strive currently has 30% amplification through perpetual preferred equity, a level MicroStrategy aims to achieve by 2029-2030, positioning Strive ahead in this specific financial structure.
• Management projects Bitcoin's value to reach millions of dollars by comparing its market capitalization potential to that of gold, suggesting a significant upside relative to current prices and traditional store-of-value assets.

Legal Proceedings

• The cautionary statement mentions the possibility of legal proceedings being instituted against Strive, Semler Scientific, or the combined company, and that the outcome of such proceedings is a risk.

Stakeholder Impact

• Shareholders of Semler Scientific are urged to vote on the merger, with the potential for significant upside from the combined entity's Bitcoin holdings and Strive's growth.
• Strive's issuance of additional Class A common stock in connection with the merger could lead to dilution for existing Strive shareholders.
• Employees and customers of both companies may experience changes to business or employee relationships as a result of the merger.
• Investors in digital credit (SATA) are positioned to receive attractive yields (12.25% interest, over 13% effective yield) and benefit from the growth of the combined company.

Next Steps

• Semler Scientific shareholders to vote on the merger by January 13, 2026.
• Closing of the merger deal is anticipated in early 2026.
• Semler Scientific expects FDA approval for its new heart disease prevention product in 2026.
• Strive plans to retire Semler's convertible note, potentially through new SATA stock issuance.

Key Dates

Recommendation

The filing presents a compelling strategic rationale for the merger, combining Semler's existing Bitcoin treasury with Strive's innovative digital credit model and amplification strategy. The strong demand for Strive's digital credit, the highly bullish long-term outlook on Bitcoin from management, and the potential for unlocking value in Semler's medical business suggest significant upside potential. The emphasis on outperforming fiat debasement and the comparison to gold's market cap indicate a belief in substantial future appreciation. While risks are present, the overall narrative points to a company well-positioned for growth in the evolving digital asset landscape, making it an attractive investment.

Keywords

Bitcoin Treasury, Digital Credit, Merger, Strive Inc, Semler Scientific, Perpetual Preferred Equity, SATA, Cryptocurrency, Corporate Governance, Healthcare, FDA Approval